15 results about "Hemophilus parasuis" patented technology

The invention relates to the technical field of immunology, in particular to a haemophilus parasuis disease mucosal vaccine as well as a preparation method and application thereof.The haemophilus parasuis disease mucosal vaccine comprises serum type 4 haemophilus parasuis H0040LV4 and serum type 5 haemophilus parasuis H0014LV5 which are preserved in the China Center for Type Culture Collection (CCTCC) on November 10, 2025 and numbered as CCTCC M 20252516 and CCTCC M 20252517; the bivalent haemophilus parasuis bivalent outer membrane vesicle vaccine prepared by secreting outer membrane vesicles has a good immune protection effect on serum type 4 and type 5 haemophilus parasuis, and compared with a control group, pathological changes of tissues such as lungs and livers of a vaccine immune group are obviously relieved. The vaccine has good immunogenicity, can stimulate comprehensive immune response, induce the organism to generate remarkable specific mucosal immunity, and simultaneously induce cellular immunity and humoral immunity response, and has a wide application prospect.

The invention discloses a porcine circovirus type 2 and haemophilus parasuis bivalent inactivated vaccine and a preparation method thereof. According to the invention, a porcine circovirus strain, a haemophilus parasuis serum type 4 strain and a haemophilus parasuis serum type 5 strain which are epidemic in situ are respectively separated and obtained, and the microbial preservation numbers of the porcine circovirus strain, the haemophilus parasuis serum type 4 strain and the haemophilus parasuis serum type 5 strain are respectively CGMCC (China General Microbiological Culture Collection Center) No.47094, CGMCC No.46698 and The separated strain or bacterial strain is prepared into a bivalent inactivated vaccine, and lentinan is added in the vaccine preparation process to enhance the immune effect; a safety evaluation result shows that local or whole-body adverse reaction caused by the bivalent vaccine does not occur, so that the safety of the bivalent vaccine is good; the immune efficacy evaluation result of the bivalent vaccine shows that the bivalent vaccine can provide complete protection for animals aiming at the in-situ epidemic porcine circovirus, haemophilus parasuis serotype 4 and haemophilus parasuis serotype 5, and has good immune protection efficacy.

The invention discloses a bivalent subunit vaccine for preventing infection of haemophilus parasuis and porcine circovirus type 2. A core antigen combination of the vaccine comprises at least one antigen protein from haemophilus parasuis, and the antigen protein is selected from Ferrin, OppA and Hem-SAP and is combined with a porcine circovirus type 2 Cap protein. Wherein the NCBI (National Center of Biotechnology Information) login number of the Ferrin, the NCBI login number of the OppA and the NCBI login number of the Hem-SAP are WP160414389.1, ACL32731.1 and WP035493594.1 respectively. The antigen protein is subjected to codon optimization, is expressed and purified through a prokaryotic expression system, and is emulsified with ISA201 or a Freund's adjuvant to prepare the vaccine. Animal experiments prove that the vaccine can excite high-level antigen specificity IgG, cell factors IFN-gamma and white IL-4 in an immune animal body, namely, specific Th1 and Th2 type immune responses are generated. The vaccine can generate an immune protection rate of up to 80% when attacked by a serum type 5 haemophilus parasuis virulent strain, and generates an effective antibody response to the porcine circovirus type 2. The vaccine provided by the invention has the advantages of definite components, good safety and strong immune protection force.

The invention discloses an application of an ST6GALNAC5 gene in prevention and treatment of swine Graisseria disease (a pathogenic bacterium causing the swine Graisseria disease by a haemophilus parasuis system), and the expression of the ST6GALNAC5 gene is inhibited in a targeted manner, so that adhesion and invasion of the haemophilus parasuis to host cells can be effectively inhibited, and cytopathy is reduced. The method is helpful for resisting cell death induced by haemophilus parasuis infection, so as to prevent the occurrence of the porcine Graisseria disease. Therefore, the ST6GALNAC5 gene can be used as an important target spot for treating the swine Graisseria disease, and has important clinical application prospects and molecular disease-resistant breeding values.

The present invention refers to the veterinary field. Particularly, it refers to a strain of Glaesserella parasuis, or a composition comprising thereof. Preferably, the strain or composition is for use in a method for the prevention and / or treatment of Glässer's disease or a condition caused by infection with a virulent Glaesserella parasuis strain. It also refers to a device suitable for administering a medicine to porcine animals characterized in that it comprises a non-virulent live strain of Glaesserella parasuis.

The invention relates to the technical field of gene engineering, and particularly discloses a serum type 5 haemophilus parasuis attenuated vaccine strain without antibody polygene deletion as well as a construction method and application of the serum type 5 haemophilus parasuis attenuated vaccine strain. According to the invention, crp, cpxAR and OmpP2 genes related to toxicity are deleted from a clinical isolated strain of a haemophilus parasuis serum type 5 virulent strain HN1570 by means of molecular biology to obtain a non-resistant polygene deleted strain HPS5 [delta] OmpP2 [delta] crp [delta] cpxAR, and the deleted strain is preserved; tests find that the attenuated live vaccine prepared by using the HPS5deltaOmpP2 deltacrp deltacpxAR strain haemophilus parasuis as a strain antigen not only has 100% protection rate on infection of type 5, but also has better cross protection force on infection of other serotype haemophilus parasuis and haemophilus parasuis incapable of being classified, and a good immune protection effect can be achieved by using a small immunization amount; the result shows that the haemophilus parasuis HPS5 [delta] OmpP2 [delta] crp [delta] cpxAR strain has good immunogenicity; the vaccine is simple in preparation process, free of resistance genes, free of toxic and side effects, good in safety, long in immune period and good in immune effect, and can be used for industrial production.

The invention belongs to the technical field of biology, relates to a haemophilus parasuis subunit vaccine as well as a preparation method and application thereof, and provides a haemophilus parasuis antigen combination which comprises a recombinant P3 protein and a recombinant P5 protein, the recombinant P3 protein is coded by a sequence shown in SEQ ID No.1, the recombinant P5 protein is coded by a sequence shown in SEQ ID No.2, and the recombinant P3 protein is coded by a sequence shown in SEQ ID No.2. The vaccine immunization can induce effective respiratory mucosa immune response, meanwhile, humoral immune and cellular immune response are remarkably induced, the safety is high, live pathogens are not involved in the vaccine preparation process, no adverse reaction is generated after immunization, and mucosa immunity can be activated when the vaccine immunizes a body; the required antigen content is obviously lower than that of the existing vaccine, the mucosal immunity is enhanced and the immune duration is prolonged by screening adjuvants, and a good immune protection effect can be provided.

The invention belongs to the technical field of biology, particularly relates to a haemophilus parasuis disease mucosal immune vaccine, a preparation method and application thereof, and provides a haemophilus parasuis antigen combination which comprises one or more of a recombinant P2 protein, a recombinant P3 protein and a recombinant P6 protein, sequences for coding the haemophilus parasuis antigen combination are shown as SEQ ID No.1-3 respectively, and the haemophilus parasuis antigen combination comprises one or more of the recombinant P2 protein, the recombinant P3 protein and the recombinant P6 protein. The haemophilus parasuis antigen combination is prepared into a haemophilus parasuis disease mucosal immune vaccine, the haemophilus parasuis disease mucosal immune vaccine is safe and free of biological safety risks, an immune body can activate comprehensive immune reactions including humoral immunity and cellular immunity, and more importantly, remarkable mucosal immunity can be induced; the antigen has good immunogenicity and good conservative property, and can provide broader spectrum protection. By means of mucous membrane immunization, conventional injection immune stress reaction is reduced, and side reaction is small. And the problem that pathogenic bacteria are not thoroughly inactivated possibly in the production of the inactivated vaccine is also solved, the pathogenic bacteria diffusion and pollution risks are reduced, and the method has a wide application prospect.

The invention discloses a continuous fermentation device for haemophilus parasuis and a culture process. The fermentation device comprises a fermentation treatment assembly, the fermentation treatment assembly comprises a vertical pipe which penetrates through the upper cover and is rotationally connected with the upper cover, the driving mechanism drives the vertical pipe to rotate so as to drive a rectangular cylinder, a rectangular piston, a short pipe, a reciprocating screw rod, a connecting pipe and an arc-shaped pipe to rotate, meanwhile, the arc-shaped pipe is gradually and horizontally arranged, and negative pressure is generated at a defoaming hole; fermentation bubbles generated by fermentation can be removed from the middle to the inner wall of the fermentation cylinder, and fermentation liquid can be mixed; the culture process comprises the following steps: S1, inoculating a culture medium with a haemophilus parasuis strain, and culturing for 28-32 hours in a CO2 constant-temperature incubator with the culture temperature of 37 DEG C and the volume fraction of 3%. According to the device, fermentation liquor and a fermentation culture medium can be fully mixed, meanwhile, effective and efficient defoaming treatment can be conducted on fermentation bubbles in a targeted mode, and the fermentation efficiency is improved.

The invention discloses a method for establishing a model for inflammation of mouse brain microvascular endothelial cells infected by haemophilus parasuis, which is used for simulating the process of porcine meningitis caused by haemophilus parasuis infection by using the mouse brain microvascular endothelial cells infected by haemophilus parasuis and researching the pathogenesis of the porcine meningitis caused by haemophilus parasuis. The optimal MOI of mouse brain microvascular endothelial cells infected by haemophilus parasuis is 1, the optimal infection time is 6 h, under the condition, the inflammatory factor level of the cells is remarkably increased, and the success rate of the cell inflammation model construction method is higher.

The application relates to the technical field of pathogenic culture, in particular to a selective culture medium for Haemophilus parasuis and a preparation method and application thereof. The selective culture medium comprises pig lung 220-280g, glucose 1-3g, agar powder 13-17g, protein peptone 8-12g, sodium chloride 3-7g, chitosan 8-12g, calcium propionate 3-7g, green plum polysaccharide 13-17g, sodium hydroxide for adjusting the pH value to 7.8+ / -0.1, and deionized water added to 1L. Compared with the TSA+NAD culture medium commonly used for the separation of the HPS strain at present, the separation rate of the HPS is increased by 20%, the separation time is shortened by 4 times, meanwhile, the biological characteristics of the separated HPS strain are not affected, the selective culture medium can be used for the rapid separation and identification of the HPS strain, has good stability, can reduce the separation and identification cost, and improves the separation accuracy.

To provide a vaccine for protecting a pig against Haemophilus parasuis, and a method to protect a pig against Haemophilus parasuis.SOLUTION: Provided is an immunogenic composition comprising a protein having at least 69% sequence identity with the protein according to a specific sequence or an immunogenic fragment of this protein, for use in a prophylactic method to protect a pig against an infection with Haemophilus parasuis. Also provided are a vaccine for protecting a pig against an infection with Haemophilus parasuis comprising the immunogenic composition and a pharmaceutically acceptable carrier, and a method to protect a pig against an infection with Haemophilus parasuis by administering the vaccine to the pig.SELECTED DRAWING: None

The application belongs to the field of biology and discloses a plasmid containing Haemophilus parasuis OmpAm outer membrane protein gene and Mycoplasma hyopneumoniae membrane protein gene; the Mycoplasma hyopneumoniae membrane protein gene is one or more combinations of Mycoplasma hyopneumoniae membrane protein P46 gene, Mycoplasma hyopneumoniae membrane protein P65 gene and Mycoplasma hyopneumoniae membrane protein P159 gene. The plasmid contains OmpAm outer membrane protein gene and Mycoplasma hyopneumoniae membrane protein gene, target genes amplified from the vector by primers are used to prepare recombinant Haemophilus parasuis by natural transformation, and one or more of Mhp antigen proteins such as P46 protein, P65 protein and P159 protein can be effectively expressed, so that the effect of double immunization is achieved. Meanwhile, the application also provides recombinant Haemophilus parasuis and application thereof.

The invention relates to the technical field of biological product science and immunology, in particular to a haemophilus parasuis outer membrane vesicle vaccine, a preparation method and application thereof.The haemophilus parasuis H0014LV5 is preserved in the China Center for Type Culture Collection on November 10, 2025, the preservation number is CCTCC M 20252517, the haemophilus parasuis H0014LV5 secretes outer membrane vesicles, and the haemophilus parasuis H0014LV5 is preserved in the China Center for Type Culture Collection on November 10, 2025. The outer membrane vesicle vaccine is rich in immunogenic protein and immunomodulatory protein, the prepared outer membrane vesicle vaccine is good in immunogenicity, a body can be induced to generate remarkable mucosal immunity through nasal mucosal immunity, meanwhile, remarkable cellular immunity and humoral immunity response are induced, the safety and toxicity dispersing risk existing in attenuated vaccines is overcome, and the vaccine is safe and reliable. The serum type-5 haemophilus parasuis H0014LV5 strain outer membrane vesicle vaccine is safe, can effectively resist type-5 haemophilus parasuis infection through vaccine immunization, and has a wide application prospect.